This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Two lower doses of CagriSema, a weekly injection combining two appetite-reducing medicines, cagrilintide and semaglutide, led to substantial weight loss in adults with obesity or with overweight and a weight-related health condition such as high blood pressure or sleep apnea, according to the REDEFINE 9 randomized controlled trial published in The Lancet Diabetes & Endocrinology journal.
The 68-week Phase IIIb trial involved 309 adults without diabetes (77% women, average age 48 years, average starting weight 109.5 kg [241 pounds]) at 24 sites in Canada, France, Germany, the U.K. and the U.S. Participants were randomly assigned to weekly injections of CagriSema at 1.7 mg of each medication (1.7 mg cagrilintide/1.7 mg semaglutide; 104 people), CagriSema at 1.0 mg of each medication (1.0 mg cagrilintide/1.0 mg semaglutide; 103 people) or placebo (102 people), alongside nutrition and physical activity counseling.
For those who remained on treatment, average weight loss at 68 weeks was 20.7% with the 1.7 mg/1.7 mg dose and 21.0% with the 1.0 mg/1.0 mg dose, compared with 2.0% with placebo. A second analysis, which included everyone regardless of whether they stopped treatment, found average weight losses of 19.4%, 18.6% and 4.6%, respectively.
7% with placebo). 4 inches) with placebo.
Source link







